Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPItello-292
jRCT2031220034Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Capivasertib + fulvestrant + CDK4/6 inhibitor with Placebo + fulvestrant + CDK4/6 inhibitor (2 arms). Started Nov 2022; status: active, not recruiting.
02
Drugs
capivasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031220034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220034.